Soligenix, Inc. – In this interview, Dr. Christopher J. Schaber, President and CEO, discusses the company’s rare disease business, including key Phase 3 clinical programs and biodefense with The Sentinel’s Brett Johnson.
Dr. Christopher J. Schaber’s Interview with OneMed Sentinel